Rep. DeLauro Statement on FDA Calling for Market Withdrawal of All Ranitidine Products
April 01, 2020
April 01, 2020
NEW HAVEN, Connecticut, April 1 -- Rep. Rosa L. DeLauro, D-Connecticut, issued the following statement:
Congresswoman Rosa DeLauro (CT-03) issued the following statement after the United States Food and Drug Administration (FDA) requested a withdrawal of all products with ranitidine--the active ingredient in Zantac--from the market. DeLauro called on FDA to recall these drugs in December of last year due to high levels of N-Nitrososdimethylamine ("NDMA"), a probable human . . .
Congresswoman Rosa DeLauro (CT-03) issued the following statement after the United States Food and Drug Administration (FDA) requested a withdrawal of all products with ranitidine--the active ingredient in Zantac--from the market. DeLauro called on FDA to recall these drugs in December of last year due to high levels of N-Nitrososdimethylamine ("NDMA"), a probable human . . .